Drug Trial Radar · NCT05400317
A Study to Evaluate the Efficacy and Safety of AD-218
Last checked: Nov 19, 2026Latest source record: Feb 5, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
520
Planned (sponsor's estimate)
Start
Jul 27, 2022
Primary completion
Mar 31, 2026
Study completion Jun 30, 2026
Sponsor
- Lead sponsor
- Addpharma Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of AD-218
Conditions
- Mixed Dyslipidemia
Interventions
AD-218Drug
PO, Once daily(QD), 12weeks
AD-218ADrug
PO, Once daily(QD), 12weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change (%) of non-HDL-C from baseline at week 12Time frame: from baseline at 12 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Yeongnam University Hospital
Daegu, Nam-gu, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.